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Dysregulation of microRNAs (miRNAs), particularly their downregulation, has been widely shown to be associated with the
development of lung cancer. Downregulation of miRNAs leads to the overactivation of their oncogene targets, while upregulation
of some miRNAs leads to inhibition of important tumor suppressors. Research has implicated cigarette smoke in miRNA
dysregulation, leading to carcinogenesis. Cigarette smoke may lead to genetic or epigenetic damage to miRNAs, many of which
map to fragile sites and some of which contain single nucleotide polymorphisms. Cigarette smoke may also cause dysregulation by
aﬀecting regulatory mechanisms controlling miRNA expression. Researchers have shown a correlation between smoke-exposure-
induced dysregulation of miRNAs and age. Furthermore, dysregulation seems to be associated with intensity and duration
of smoke exposure and duration of cessation. Longer exposure at a threshold level is needed for irreversibility of changes in
expression. Better understanding of miRNA dysregulation may allow for improved biomonitoring and treatment regimens for
lung cancer.
1.Introduction
In the United States, lung cancer is the second most common
cancer to occur in men and women [1], yet with a ﬁve-
year survival rate of only 15%, lung cancer represents the
leading cause of cancer-related deaths [1, 2]. This poor
survival is largely a product of lack of early screenable
biomarkers, which leads to detection of the cancer at an
advanced and typically untreatable stage [2]. Furthermore,
histologic classiﬁcation of lung cancer is limited, given the
genotypic heterogeneity among cells of a similar type [3].
Such heterogeneity causes varied responses to treatment
and limits the eﬃcacy of a single or generalized therapy.
Previous research has analyzed gene expression signatures
to elucidate the heterogeneity of lung cancers, allowing
for more accurate diagnosis and prognosis and permitting
creation of more targeted therapies [3, 4]. Nevertheless,
as mRNAs may be regulated posttranscriptionally, only
determining mRNA expression may not fully portray the
biological mechanisms involved in cancer initiation and
progression [2]. Computer models have predicted that
miRNAs, which posttranscriptionally suppresses translation
of mRNA, accounts for 1/3 of total regulation of the genome
[5] .D y s r e g u l a t i o no fm i R N A ,t h u s ,c a nh a v ea ni m p o r t a n t
consequence in the dysregulation of genes, and miRNA
analysis can provide a more comprehensive understanding
of lung cancer pathogenesis. Moreover, research has found
that exposure to cigarette smoke can lead to alterations in
miRNAs, establishing a pivotal connection between cigarette
smoke and carcinogenesis [6]. Elucidating the dynamics
and carcinogenic mechanisms behind the cigarette smoke-
induced dysregulation of miRNAs will contribute to the
developmentofmoreeﬀectivelungcancerdiagnosis,chemo-
prevention, and therapy.
2.miRNA Processing
About 1000 human miRNAs have been identiﬁed (Mir-
Base), and while much about their function and speciﬁc
biological targets is unknown, researchers are clarifying the2 Pulmonary Medicine
general mechanisms of miRNA expression (transcription
and processing) and suppression of mRNA [2]. Processing
begins with a large primary transcript, pri-miRNA, of >100
nucleotidesinlength,transcribedbyRNApolymeraseII.The
newly transcribed pri-miRNA is bound to double-stranded
RNA binding domain protein within the nucleus. The pri-
miRNA then binds to DiGeorge syndrome critical region
gene 8 protein (DGCR8) and an RNase III endonuclease
(Drosha). This Microprocessor complex cleaves the pri-
miRNA to a 70 nucleotide imperfect stem loop precursor
called pre-miRNA. Exportin 5 and Ran GTPase then trans-
port pre-miRNA from the nucleus to the cytoplasm where
it forms a second processing complex containing the RNase
IIIendonucleaseDicerandthetransactivatingresponseRNA
binding protein (TRBP). This complex cuts the stem loop
pre-miRNA into a double-stranded miRNA of about 22
nucleotides in length. The strands are separated and AGO
proteins help incorporate the antisense strand into the RISC
complex. Once in the RISC complex, the AGO proteins
bind in the 3  end of mRNA, stabilizing the interaction
between the miRNA and mRNA. The miRNA targets the
speciﬁc mRNAs through complementarity between the 5 
end of the miRNA and the 3  UTR of the mRNA. MiRNAs
that have perfect complementarity with the duplexed mRNA
initiate the RNA-mediated interference pathway, through
which the target mRNA is cleaved by the AGO proteins and
then degraded [2, 7]. Imperfectly binding miRNAs prevent
translationofthetargetmRNAsandcausesmRNAinstability
[7].
3.DysregulationofmiRNA
Severalstudieshaverecentlyshownthatexposuretocigarette
smoke in both humans and rats leads to global alterations
in miRNA expression. Table 1 provides a summary of
important miRNAs that are signiﬁcantly dysregulated by
cigarette smoke and are implicated in carcinogenesis. After
exposing rats to environmental cigarette smoke for 28 days
and examining miRNA expression in normal lung cells, the
Izzotti group found that of the 484 miRNAs analyzed, 126
miRNAs (26%) were downregulated twofold. Of the 484
miRNAs analyzed, only 7 miRNAs (1.4%) were upregulated
twofold. Moreover, 24 miRNAs were downregulated three-
fold with a statistically signiﬁcant variation between the rats
exposed to environmental smoke and those not exposed [8].
Cigarette-smoke-induced dysregulation of miRNA has been
demonstrated in humans as well. Examining the bronchial
airway epithelium of current smokers and never smokers,
Schembri et al. found 28 miRNAs to be signiﬁcantly diﬀer-
entially expressed. Of the 28 dysregulated miRNAs, 23 were
downregulated [9]. MiR-30a was commonly downregulated
in both humans and rats [8, 9]. Among studies analyzing
cigarette-smoke-dysregulated miRNA, the downregulation
of miRNA seems to be more common than upregulation [8–
10].WiththeirpivotalregulationofmRNAs,carcinogenslike
cigarette smoke that cause alterations in miRNA levels can
cause miRNAs to act as oncogenes (or fail to act as tumor
suppressors), thereby rendering smokers susceptible to the
development of lung cancer [10].
4. Mechanisms of Cigarette-Smoke-Induced
miRNA Dysregulation
The exact mechanism by which cigarette smoke causes this
dangerous dysregulation remains unknown; nevertheless,
recent studies are beginning to oﬀer theories elucidating the
mechanism. Figure 1 depicts basic mechanisms by which
cigarette smoke may induce dysregulation of miRNA and
may lead to cell cycle dysregulation. Tobacco smoke contains
free radicals and oxidative compounds which are highly
mutagenic [8]. The tar phase of smoke contains a quinone
and hydroquinone complex within the tarry matrix. This
complex is highly oxidative, producing hydrogen peroxide
and hydroxyl radicals. The gas phase of cigarette smoke
is equally harmful, containing small oxygen and carbon-
centered radicals. Such radicals have been demonstrated
to react with DNA in vitro [11]. For example, aqueous
cigarette tar (ACT) solutions have been shown to react
with DNA nucleotides to create adducts like 8-hydroxy-2 
deoxyguanosine, which has been used as a biomarker for
carcinogenesis [12].
In addition to the high toxicity and mutagenicity
of cigarette smoke, the genes for miRNAs often lie in
particularly mutable parts of the genome. After mapping
186 miRNA genes and comparing their location to sites
previously reported as genetically mutated, Calin et al. found
that the miRNAs are often located in “fragile sites” of the
genome [13]. Esquela-Kerscher and Slack noted that many
human homologues of the let-7 family (see below) map
to such fragile sites [7]. Furthermore, as cigarette smoke
seems to act through continued exposure rather than a single
initiating event, some miRNA alterations may also be a
product of disruption in epigenetics rather than initiating
mutational events [8].
In addition to being located at fragilesites in thegenome,
many miRNAs are characterized by single polymorphisms
rendering them even more susceptible to genetic damage
by cigarette smoke. The Izzotti et al. experiment found
ﬁve cigarette smoke downregulated miRNAs with single
nucleotide polymorphisms [8]. One of these miRNAs is
miR-125. In addition to the family members mapping to
11q23-q24 and 21q11.1, fragile sites commonly deleted in
lung cancer patients, mir-125a h a saG / Up o l y m o r p h i s ma t
nucleotide 8 [8, 13, 14]. The uracil polymorphism inhibits
processing of the primary to the precursor miRNA. With
a single nucleotide altering its processing, this miRNA
is more susceptible to genetic damage and subsequent
downregulation by carcinogens like cigarette smoke [8,
14]. miR-125 normally suppresses ERBB7, the oncogenic
coding sequence for EGFR, a growth factor receptor often
overexpressed in carcinomas [14, 15]. Therefore, if genetic
damage inhibits processing and downregulates miR-125,
it may lose its functionality as a tumor suppressor of
EGFR. Given that some miRNAs have easily mutable single
nucleotide polymorphisms which can singly determine their
functionality, alterations in miRNA levels may be an early
event in cigarette-smoke-induced carcinogenesis [8]. In
addition to their importance in early carcinogenesis, single
nucleotide polymorphisms in miRNA genes may accountPulmonary Medicine 3
Table 1: Important miRNAs signiﬁcantly dysregulated by cigarette smoke and implicated in carcinogenesis [8, 14, 32, 36].
miRNA Targets Biological eﬀects of dysregulation Comments on dysregulation
Downregulated
let-7a, b,
c, f Ras, CDK6, cyclin A2 Ras oncogene activation, cell proliferation,
angiogenesis
Normally, let-7 is a master regulator of cell
proliferation
mir-26a TGF TGF overexpression, angiogenesis Greater downregulation in postweanling
female mice
mir-30a EFG pathway, NF-κB
inhibitors, CDC40
Cell cycle progression, cell adhesion, protein
repair, EFG activation, stress response (NF-κB
activation)
Downregulated in both humans and rats
mir-30c EFG pathway, NF-κB
inhibitors, CDC41
Chemoresistance, cell cycle progression, cell
adhesion, protein repair, EFG activation, stress
response (NF-κB activation)
Downregulation leads to chemoresistance
mediated through MDR-1
mir-34 a–c CDK4, CDK6, cyclin E2,
and E2F3 Cell cycle arrest inhibited Mutations in p53 can lead to its
downregulation
mir-122a heme-oxygenase 1 Increased antioxidant activity in liver and lungs Involved in stress response
mir-125a ERBB7 (gene for EGFR) ERBB7 oncogene activation Maps to fragile site with G/U polymorphism
mir-140 p53 pathway Cell cycle arrest inhibited Greater downregulated in postweanling
female mice
mir-345 Ras pathway Ras oncogene activation, cell proliferation Downregulation is persistent for at least one
week after cessation
Upregulated
mir-294
Zinc ﬁnger protein 697,
AT-rich interactive
domain 4A
Increase in transcription Upregulated 10.4-fold in Izzotti et al. [8].
miRNA gene
mRNA (CDK4, CDK6, cyclin E2, etc.)
Transcription
and
p53
Activates
Nucleus Cytoplasm
Translocation RISC
miRNA in RISC complex
Processing
Pre-miRNA Pre-miRNA
Binds to 5 or 3 UTR
Decay or inhibition of mRNA Cell cycle regulation
Transcriptional regulator
Regulatory gene (like p53)
processing
(let-7, miR-34)
Figure 1: Simpliﬁed overview of the mechanisms by which cigarette smoke induces dysregulation of miRNA (red arrows) and subsequent
carcinogenesis. CS can lead to genetic mutations in miRNA transcriptional regulators, like P53. Dysregulation of P53, an activator of miRNA
transcription, leads to downregulation of miRNA, like miR-34. CS can also lead to epigenetic or genetic mutations in the miRNA gene itself,
leading to dysregulation of transcription. Both downregulation and upregulation of miRNA can allow for cell proliferation if the miRNA
is a tumor suppressor or oncogene, respectively. The red arrows indicate direct action of CS on miRNA production. The red “X’s” indicate
inhibition of a normal process (indicated by black arrows).4 Pulmonary Medicine
for variations in carcinogenic susceptibility among smokers
[16].
Cigarette smoke may also cause the dysregulation of
miRNAs by disrupting miRNA regulatory mechanisms, like
the P53 pathway. The tumor suppressor P53 is an important
regulatory protein that can induce cell cycle arrest, cell
growth, apoptosis, and angiogenesis [17]. Over half of all
lung cancers have a mutation in P53, and the frequency of
these mutations seems to be dependent on smoking status
and number of cigarettes smoked [18–20]. Smoke seems
to leave a unique “molecular signature” on the P53 gene
in smoke-exposed lung tumors. Smoke exposure is often
correlated with an increase in G to T transversions in the
gene, possibly caused by a reaction with polycyclic aromatic
hydrocarbons in tobacco smoke [21]. Normally, P53 directly
transactivates and promotes the transcription of mir-34a–c,
which in turn induces cell cycle arrest by targeting proteins
suchasCDK4,CDK6,cyclinE2,andE2F3[17,21].However,
once mutated, P53 may fail to eﬃciently induce miR-34
expression, leading to miR-34 s downregulation. Indeed,
as Izzotti et al. showed, miR-34 is, in fact, downregulated
in the presence of environmental cigarette smoke. (In this
experiment, it was speciﬁcally downregulated a striking 3.6-
fold [8].) Nevertheless, this dysregulation may not entirely
depend on the loss of P53, as miR-34 downregulation has
been shown to independently diminish the eﬃciency of the
P53-dependent apoptosis, suggesting its independent and
crucial role in the p53 pathway and in tumorogenesis [22,
23].
One family of miRNA, the let-7 family, has been closely
studied for its role in the development of lung cancer and
for its potential use in therapy; recently, exposure to cigarette
smoke has been implicated in the downregulation of let-
7,o ﬀering one possible mechanism for carcinogenesis. let-
7 and its family are highly conserved across animal species
[8].Humanshavetenmaturelet-7 sequences,denotedbythe
letters “a” through “k,” and 13 precursor let-7 species [24].
One of the genes that let-7 seems to directly regulate is the
oncogene RAS. Ras proteins are GTPase proteins associated
with the plasma membrane. The proteins promote cellular
growth and diﬀerentiation. Approximately 15–30% of all
human tumors have mutations in RAS that stimulate Ras
overexpression and cause oncogenic transformation of the
cell [7]. By targeting LCSs (let-7 complementary sites) in the
3  UTR of RAS, let-7 post-transcriptionally downregulates
the expression of the gene. In lung tumors, let-7 seems to
be downregulated compared to normal tissue. As a response
to the decreased miRNA repression, Ras is upregulated
[25]. Other direct targets of let-7 include cyclins like A2,
which signals G1-S and G2-M transitions, and CDKs like
CDK6. CDK6 interacts with D cyclins to phosphorylate RB1,
ultimately promoting the G1 phase of the cell cycle [26].
The activator of S-phase kinase (ASK), necessary for DNA
replication in the G1 to S transition, is also under the control
of the let-7 family. In total, Johnson et al. found that changes
in let-7 levels signiﬁcantly aﬀected close to 200 genes in both
liver and lung cells. Thus, the let-7 family seems to be a
“master regulator” of cell proliferation, directly or indirectly
controlling the expression of many cell-cycle genes. In the
same experiment, the addition of synthetic let-7 caused a cell
cycle deﬁciency, in which the percentage of cells stuck in the
G0-G1 phase increased. At normal levels, it seems that let-
7 helps delay the G1-S transition [27]. The downregulation
of this master regulator seems to be a typical and initiating
event in the development of lung cancer, promoting cell
progression through the G1-S transition [2, 27, 28].
The mechanism of let-7 carcinogenesis is further under-
stood in the context of smoke exposure. Several experi-
ments have found signiﬁcant downregulation of let-7 and
upregulation of its targets after exposure to cigarette smoke
[8, 29, 30]. Izzotti et al. found a large 4.6-fold decrease in let-
7c in lung tissue of rats after only four weeks of exposure to
environmental cigarette smoke [8]. Such data supports the
g r o u p ’ sp r e v i o u sp r o t e o m ed a t at h a tlet-7-targeted cyclins
and CDKs were upregulated in the same tissue [30].
In addition to tumor suppressors like let-7,m i R N A s
may serve as oncogenes; subsequently, their cigarette-smoke-
induced upregulation can contribute to carcinogenesis [5].
In the Izzotti et al.’s experiment, after rats were exposed to
environmentalcigarettesmokeforfourweeks,theexpression
of484miRNAsinthelungtissuewasanalyzed.OfthesemiR-
NAs, while 126 (26%) showed a twofold downregulation,
o n l y7m i R N A s( 1 . 4 % )s h o w e da nu p r e g u l a t i o no ft w o f o l d
compared to sham-air exposed rats. Similarly, compared
with sham rats, while 26 miRNAs were signiﬁcantly down-
regulated threefold, only 1 was signiﬁcantly upregulated.
This miRNA, miR-294, was upregulated a signiﬁcant 10.7-
fold. In normal expression, miR-294 silences transcriptional
repressor genes like zinc ﬁnger protein 697 and AT-rich
interactive domain 4A. However, when upregulated, miR-
294 promotes a global increase in transcription, potentially
becoming oncogenic [8].
5.Age Association,Dose Responsiveness,
andPersistence of Dysregulation
Regardless of whether miRNAs serve as oncogenes or tumor
suppressors, their cigarette-smoke-induced dysregulation
seems to vary with age. In another experiment by the
Izzotti group, newborn mice were exposed to environmental
cigarettesmokeforﬁveweeks,correspondingtotheweanling
period. The miRNA expression in their lung tissue was
subsequently compared to postnatal untreated mice, adult
mice exposed to ﬁve weeks of cigarette smoke, and newborn
and adult mice exposed to sham air for ﬁve weeks. In mice
not exposed to smoke, the largest variations in miRNA
occurred during the weanling period. This seems congruent
with that fact that there is a large amount of oxidative
stress in the lung of a newborn during the transition
from “the maternal-mediated respiration of the fetus to the
autonomous pulmonary respiration of the newborn.” All 11
miRNAs that were signiﬁcantly altered from birth to the end
of the weanling period are involved in early life processes.
Several were involved in embryological development and
morphologicalchanges,“reﬂectingthefactthatdevelopment
and maturation of the lung are completed after birth” [31].
During this transition to pulmonary respiration, oxidative
stress on the newborn lung induces many genomic andPulmonary Medicine 5
postgenomic alterations, including a signiﬁcant increase in
bulky DNA adducts and oxidatively damaged DNA [32].
Cells may respond to such genomic damages by increasing
expression of stress-response genes through downregulation
of miRNAs. In the experiment, 7 downregulated miRNAs
in the postweanlings were involved in proliferation and
diﬀerentiation, processes contributing to stress-response
during lung development [31].
In mice exposed to environmental cigarette smoke, both
the adult and postweanling mice revealed predominantly
downregulated miRNAs. Since many of the downregulated
miRNAs allow for the overactivation of oncogenes, miRNA
variation in both postweanlings and adults can contribute
to miRNA-mediated carcinogenesis. Among the miRNAs
downregulated were let-7b, miR-26a, miR-30c, miR-124a,
miR-125a, miR-192, and miR-431, the downregulation of
which promotes activation of oncogenes and growth factors
like Ras, ERBB2, EGF, and TGF. Tumor suppressors like let-7
andeﬀectorsofthep53pathway,miR-34bandmiR-140,were
also downregulated, revealing their possible role in smoke-
mediated carcinogenesis.
Nevertheless,thepostweanling,smoke-exposedmicehad
a greater downregulation than the adult, smoke-exposed
mice. MiR-26a and miR-140 had the greatest diﬀerence in
downregulation, between postweanling females and to adult
females. The downregulation of miR-26a leads to the overex-
pression of TGF growth factor, whereas the downregulation
of miR-140 suppresses the p53 pathway [32]. These two
pathways oﬀer possible mechanisms of carcinogenesis in
mice exposed early in life. Mice exposed to smoke early
in life do, indeed, have a high incidence and development
of lung tumors. In the study by Balansky et al., newborn
mice exposed to mainstream cigarette smoke (MCS) quickly
developed a large yield of lung microadenomas and ade-
nomas in addition to bronchial and alveolar hyperplasia.
The untreated control mice had no tumors. The authors
posit that the mice have a “striking” “susceptibility...to the
carcinogenicityofMCS,whenexposurestartsfewhoursafter
birth” [33]. The great downregulation of miRNAs in ECS-
exposedweanlingmicemaybecorrelatedwiththis“striking”
tumorogenesis.
Compared with adult mice, the high susceptibility of
newborn mice to carcinogenesis may be a product of the
synchronizationofthesmoke-exposurewiththeirvulnerable
lung maturation process. During this maturation process,
natural oxidative damage of the DNA occurs in addition to
smoke-caused oxidative damage. As newborn organs have an
increased rate of proliferation, there is higher risk for clonal
expansion of mutated cells [33, 34]. The downregulation
of miRNAs in neonatal mice may allow such hyperplasia
to go unchecked [32, 33]. Finally, neonatal mice have
“hypothetically, an increased probability for the involvement
of stem cells, which have been shown to have an increased
susceptibility to genotoxic carcinogens” [35].
Though many studies have proﬁled the smoke-induce
diﬀerential expression of miRNA, few have evaluated the
dynamics and persistence of such alterations. The Izzotti
grouphasbeguninitialresearchintothedose-responsiveness
and persistence of smoke-induced miRNA alterations. In the
Izzotti experiment, neonatal mice were exposed to sham air
and three diﬀerent doses of smoke: 119mg/m3, 292mg/m3,
and 438mg/m3 total particulate matter (TPM) for four
weeks. Lung tissue exposed to each of the doses was analyzed
for bulky DNA adduct and 8-oxodGuo levels, as well as
diﬀerential expression of miRNA. In the 119 and 292mg/m3
TPM-dosed lung tissue, bulky DNA adduct and 8-oxodGuo
levels signiﬁcantly increased. However, miRNA expression
was not altered. Only at the highest dose of 438mg/m3
TPM did the miRNA expression change signiﬁcantly. This
dose responsiveness, thus, indicates that a threshold dose of
cigarette smoke exposure is required to alter miRNA expres-
sion and induce miRNA-mediated carcinogenesis [36].
In the second phase of the experiment, the Izzotti group
analyzed the persistence of miRNA expression alterations.
T h eg r o u pc o m p a r e dD N Ad a m a g ea n dm i R N Ae x p r e s s i o n
in mice exposed to 438mg/m3 TPM that were sacriﬁced
immediately, after one week of cessation, and after four
weeks of cessation. After one week of cessation, miRNA
downregulation was decreased (Figure 2). Thus, the team
concluded that four weeks of smoke exposure, even at the
highest dose, was too short of a time to induce irreversible
changes in miRNA expression. In light of the reversible
downregulation of miRNA, 4 weeks is too short to induce
miRNA changes that could be involved in smoke-induced
carcinogenesis [36]. The longer the exposure to cigarette
smoke, the longer the alterations in lung miRNA expression
persist and are potentially pathological. Mice exposed to
mainstream cigarette smoke for four months experienced
alterations in miRNA which lasted for three months [14].
The reversibility of cigarette smoke-induced miRNA
changes in the lung may be a manifestation of the adaptive
response mechanisms of the lung cells. Upon less intense
and shorter exposure to cigarette smoke, cells down-regulate
many miRNAs to “activate adaptive and protective functions
aimed at defending the respiratory tract from the adverse
eﬀects” of the smoke. Indeed, many of the downregulated
miRNAs in cigarette smoke exposure studies are involved
in this response to mediate the toxic eﬀects of smoke.
Such miRNAs include miR-122a, miR-431, and miR-99b
[31]. MiR-122 downregulation increases heme oxygenase-1
(HO-1) activity, which has been found to act as an antiox-
idant in both the liver and the lungs of cigarette smoke-
exposed mice [37, 38] MiR-431 is involved in protein repair,
while miR-99b induces apoptosis of smoke-damaged cells
[31].OneofthemostsigniﬁcantlydownregulatedmiRNAsis
miR-30a[8,36].ThedownregulationofthismiRNAthrough
smoke-exposure may allow for an increased release of NF-
κBinhibitors,allowingforNF-κB’snucleartranslocationand
activation. Thus, downregulation of miR-30a activates the
NF-κB pathway and stimulates an inﬂammatory response
[8, 30, 36]. Other downregulated miRNAs, like let-7a,m i R -
30b, miR-30c, miR-124a, miR-219, and miR-376, increase
cell proliferation. Cell proliferation, known to increase in
the lungs upon exposure to smoke, replenishes the smoke
damaged lung tissue [38, 39].
Although the miRNAs studied had reversible alterations
inexpressionthatcontributedtotheadaptiveresponse,some
miRNAs took a longer time to recover to normal levels;6 Pulmonary Medicine
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Figure 2: Persistence of miRNA in lung tissue: cartoon of a graph
adapted from [36] of the intensity of expression of 697 miRNAs in
the lung tissue of untreated mice or mice exposed to 438mg/m3
TPM of cigarette smoke for 4 weeks. The mice were sacriﬁced either
immediately (1 day) or 1 week after cessation. The blue to red
gradient represents the least to most intense miRNA expressions,
respectively. The graph reveals that most of the changes in miRNA
expression were reversed after 1 week of cessation.
surprisingly, those that persisted for longer seemed to be
miRNAs previously implicated in carcinogenesis. Many of
the miRNAs that remained downregulated after one week
of cessation were involved in the P53 pathway. MiR-34b,
as mentioned before, is a main eﬀector of the P53 tumor
suppressor pathway. MiR-345, miR-421, and miR-450, also
persisting for at least one week of cessation, are normally
involved in the inhibition of the RAS oncogene pathway. The
longer oncogenic miRNA alterations like these persist, the
more likely they will contribute to the dysregulation of the
lung cells and the initiation of cancer [36].
6. Conclusions
The Izzotti study clarifying dose-responsiveness and per-
sistence of miRNA alterations shed light on the timeline
of cigarette-smoke-induced carcinogenesis. Cigarette smoke
causesirreversiblemiRNAexpressionchangesonlyifanimals
are exposed for a suﬃcient period of time at high doses
surpassing a threshold [36]. More in depth research is
needed as to what doses and length of time are needed for
such irreversibility in both rodents and humans. However,
such conclusions about the dynamics of cigarette smoke
regulated miRNA expression have implications for public
health. The International Agency for Research on Cancer
(IARC)citesthat“insmokers,themostimportantparameter
of smoking that aﬀects lung cancer risk is the duration
of regular smoking, although the risk also increases with
the number of cigarettes smoked per day.” This statement
supports the idea that duration of smoke exposure seems
correlated with reversibility of carcinogenic miRNA changes.
Duration seems more important than intensity, as it seems
there is a threshold level of smoke below which carcinogenic
changesmaybenegligible.Furthermore,similartotheIzzotti
et al. study of persistence [36], smoker cessation for at least
one to four years is correlated with a signiﬁcantly lower risk
of lung cancer. The relative risk for lung cancer decreases
further with increased cessation time. Though more research
is needed, reversible changes in miRNA expression may be
associated with this mutability of risk [40].
6.1. miRNA as a Biomonitoring Tool. With the recent re-
search into miRNA expression in smoke exposed lung tissue,
miRNA expression proﬁling may soon become an important
toolforbiomonitoringtheriskanddevelopmentoflungcan-
cer. MiRNA expression proﬁles have proven to have higher
sensitivity to cigarette smoke (larger changes in quantity
expressed)thanotherproteomicandtranscriptomicproﬁles.
For example, of 484 miRNAs proﬁled, 126 (26.0%) had at
least twofold downregulation. In the same tissue, cigarette
smoke induced a twofold upregulation of only 2.9% of genes
and 9.7% of proteins [8]. This increased sensitivity could
lead to more detailed monitoring of activated and inhibited
pathways in cancer progression, allowing for the elaboration
of carcinogenic mechanisms. More sensitivity could also
allow for improved estimation of cancer risk.
New techniques in miRNA monitoring could also lead
to better cancer diagnosis. In the past, miRNA microarrays
have been used to examine the tissue-speciﬁc expression
proﬁles (called signatures) of miRNA genes [10, 41]. Lu et
al., however, developed a new and more accurate technique
to study miRNA signatures: the bead-based ﬂow cytometry
technique. This technique involves carboxylating oligonu-
cleotide probes to 5-micron polystyrene beads. Each bead
was ﬁlled with two ﬂuorescent dyes, creating variations of
colors and allowing for one color to represent one miRNA
being examined. After hybridizing the miRNAs to the probe,
a ﬂow cytometer is used to detect color and intensity of the
beads, thus, quantifying miRNA expression. This method
has proven a highly accurate way to diagnose and stage
tumors: the proﬁles can be used to diﬀerentiate normal and
tumor tissues, classify cellular diﬀerentiation, and determine
developmental origin. Compared to mRNA tumor proﬁling,
with relatively few miRNAs analyzed, miRNA proﬁling
accurately classiﬁed tumors that were poorly diﬀerentiated
[41].
Moreover, miRNA signatures can predict an accurate
prognosis of the tumor [7]. In a recent study, neonatal mice
were exposed to 723mg/m3 TPM of mainstream cigarette
smoke for 120 days and were taken oﬀ treatment for three
months. Some mice had preexisting pulmonary adenomas,
carcinomas, or pneumonias, and some of these were treated
with either the N-acetyl-l-cysteine (NAC), 5,6-benzoﬂavone,
or phenethyl isothiocyanate (PEITC) chemopreventatives.
The miRNA expression proﬁles were compared for the
diﬀerent cancers, and it was found that each type of cancer
had speciﬁc dysregulation of miRNA that was signiﬁcantly
predictive of the diagnosis. For example, pulmonary ade-
noma had a predictive downregulation in miR-10b, miR-
30c, and miR-138. miR-10b is overexpressed in adenomas in
proportion to the aggressiveness of the tumor. Its downregu-
lation in this study supports that the tumor’s prognosis was
benign [14].Pulmonary Medicine 7
6.2. Chemoprevention of miRNA Dysregulation. Proﬁling
miRNAs can also predict the eﬃcacy of chemopreven-
tion [7]. miR-30c and miR-138 are both implicated in
chemotherapy resistance and coordinated by the expression
of the MDR-1 gene. Remarkably, in mice treated with
NAC or PEITC, both miRNAs are upregulated, potentially
diminishing chemoresistance. Such upregulation reveals the
eﬃcacy of both treatments. Bronchoalveolar carcinoma had
a predictive and striking downregulation of let-7 by 6.1-fold.
This downregulation was attenuated through chemopreven-
tionwithPEITC[14].Inadiﬀerentexperiment,484miRNAs
from lung tissue of cigarette-exposed rats were monitored
for their response to the chemopreventative agents NAC,
oltipraz (OPZ), indole-3-carbinol (I3C), PEITC, and 5,6
benzoﬂavone (BF). None of the chemoagents had a signif-
icant eﬀect on the baseline miRNA levels of the untreated
group of mice, signifying the agents’ safety. At the same time,
all of these agents modulate miRNA levels in the smoke-
exposed rats. Rats treated with a combination of OPZ and
PEITCsawanearnormalizationofseveralmiRNAslike let-7,
pre-miR-191, and pre-miR-222. This upregulation suggests a
reduction in proliferation. By allowing researchers to predict
the eﬃcacy of chemopreventative agents, researchers can
screen agents and continue to develop those that seem
highly eﬀective. In the long-run, this increases cost and
time eﬃciency of chemopreventative research. Many of
the miRNAs targeted by the chemopreventative agents in
this experiment (let-7a, miR-125b, miR-140s, and pre-miR-
146) are polymorphic in humans. It may be possible to
use miRNA proﬁling to understand not only individual
susceptibility to smoke-induced carcinogenesis, but also how
these polymorphisms and chemopreventative agents interact
to regulate the expression of miRNA. It, thus, might be
possible to predict how speciﬁc individuals might react to
certain chemopreventative agents. In the future, miRNA
proﬁling may allow for personalized and highly eﬀective
cancer prevention [42].
6.3. miRNA as a Therapeutic Agent. MiRNA proﬁling in
cigarette-smoke-exposed tissue and lung cancer tissues can
and has contributed to the development of novel therapies
using miRNA itself. The downregulation of tumor suppres-
sor miRNAs, like let-7, is critical to lung carcinogenesis.
Exogenous delivery of miRNAs like let-7 to patients at risk
of cancer may prevent its development. Slack and Weidhaas
hypothesize that patients with lung tumors containing
activatingKRASmutationswouldalsobeidealcandidatesfor
such a therapy; exogenous let-7 would add another block to
the development of the cancer. Slack and Weidhaas suggest
two possible methods of miRNA delivery, including viral
genetherapyormodiﬁedmiRNA[28].Liposomaldeliveryof
miRNA might also be useful. All of these approaches would
require the delivery of hairpin and ﬂanking sequences of pre-
miRNA. Through stimulation of tissue-speciﬁc promoters,
suchtherapywouldrelyonendogenousregulationtoprocess
and promote miRNA-mediated repression of genes. The
Slack group has found success with let-7 therapy; its delivery
not only seems to prevent the development of premalignant
lung tumors, but also shrinks those RAS-activated tumors
[7]. In overexpressed miRNAs, antisense oligonucleotides
for the dysregulated miRNAs can be synthetically cre-
ated. These antisense molecules, called antimiRNA oligonu-
cleotides (AMOs), work by targeting exactly complemen-
tary sequences in the overexpressed miRNA. Conjugated
with cholesterol for delivery, these AMOs have successfully
inhibited the oncogenic miRNA activity in mice, and they
seem to be much more stable and less toxic than other
cancer treatments [43, 44]. While it is unlikely that miRNA
t h e r a p ya l o n ew i l lb es u ﬃciently eﬀective, the therapy
may eﬀectively treat cancer when combined with other
treatments. For example, tumors with an overactive EGFR-
Ras pathway are very common but are often untreatable due
to the chemoresistance of the cells [28]. Use of farnesylation
inhibitors to inhibit RAS membrane targeting and inhibition
of EGFR have beenineﬀective[45,46].Theineﬃcacy ofsuch
treatments is probably a result of the lack of speciﬁcity of
the inhibitors for the Ras pathway [47]. With the speciﬁc
complementarity of miRNA, exogenous delivery of let-
7 could inhibit RAS membrane targeting, “bypassing the
radioprotective eﬀects of the EGFR-RAS pathway [28]”.
6.4. Final Thoughts. Dysregulation of miRNAs, and partic-
ularly their downregulation, has been widely shown to be
associated with the development of lung cancer. Recently,
research has implicated cigarette smoke in the induction
of such miRNA dysregulation, leading to carcinogenesis.
Scientistshavefoundthatcigarettesmokemayleadtogenetic
or epigenetic damage of miRNA genes, many of which are
at fragile sites and many of which have vulnerable single
nucleotide polymorphisms. Cigarette smoke may also cause
dysregulation by aﬀecting regulatory mechanisms like the
p53 tumor suppressor. The downregulation of miRNAs like
the let-7 family leads to the overactivation of their oncogene
targets. Upregulation in a few miRNAs leads to inhibition
of important tumor suppressors. Recently, researchers have
shown a correlation between smoke exposure-induced dys-
regulation of miRNAs and age; newborn rodents seem to
be the most vulnerable to both miRNA downregulation
and tumorogenesis. This is perhaps due to the signiﬁcant
natural oxidative stress and the vulnerability of their newly
developing lungs. Furthermore, the dysregulation seems to
be associated with intensity of smoke exposure, duration
of exposure, and duration of cessation. Dose-responsiveness
studies of the dysregulation suggest a threshold of exposure
is necessary for signiﬁcant changes in miRNA expression.
Short-term exposure leads to reversible changes that seem
associated with an adaptive response mechanism. Longer
exposure is needed for irreversibility of changes in expres-
sion. The exact mechanisms and dynamics of cigarette-
smoke-induced dysregulation are largely unknown. Never-
theless, with a growing understanding, researchers may be
able to elucidate an important player in cigarette-smoke-
caused lung carcinogenesis. With better understanding of
miRNA, researchers may have the chance to improve
biomonitoring and treatment technologies. Deﬁning the
role of miRNA in cigarette-smoke carcinogenesis could lead
to improved diagnosis, prognosis, and treatment of lung
cancer.8 Pulmonary Medicine
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